Skip to content
Peptide research

Ecnoglutide

Also known as XW003
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A cAMP-biased GLP-1 receptor agonist marketed for weight loss and glucose control in type 2 diabetes. Human data are unusually strong for a peptide, roughly 15% weight loss at 48 weeks plus A1c and liver fat gains, but nearly all from Chinese trials, unconfirmed elsewhere. Risks include GLP-1 nausea, an unresolved theoretical thyroid tumor signal, and a new mechanism with no long-term safety record. Not an approved drug in the US; supply warrants caution.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Exceptional weight loss (15.4% at 48 weeks, no plateau observed)

    High

    Peer-reviewed phase 3 RCT showed 13.2% loss at 40 weeks; 48-week 15.4% figure is company-reported.

  • 92.8% of patients achieved clinically meaningful >=5% weight loss

    High

    Randomized trial confirmed high response rates; the 92.8% figure comes from company reporting.

  • Superior HbA1c reduction in T2D (up to 2.43% from baseline at 1.2 mg)

    High

    Two randomized phase 3 trials showed greater HbA1c reduction than placebo and dulaglutide.

Evidence limits

Evidence Level
Strong Evidence (Phase 3, Approved in China)

Ecnoglutide has completed Phase 3 trials for both obesity (SLIMMER) and type 2 diabetes (EECOH-1) with results published in top-tier journals (The Lancet Diabetes & Endocrinology, Nature Communications). It has been approved by China's NMPA for chronic weight management. Phase 3 data demonstrated 15.4% weight loss at 48 weeks and 2.43% HbA1c reduction at 24 weeks. All trials were conducted in Chinese populations; global Phase 3 data are not yet available.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events (GLP-1 class effects)

    High
  • Limited data outside Chinese populations

    High
  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical
  • Novel biased mechanism with limited long-term safety data

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.